Business
ProtoKinetix Updates Progress Toward Clinical Trial Application for AAGP™
ProtoKinetix Updates Progress Toward Clinical Trial Application for AAGP™.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\n \n ProtoKinetix, Incorporated (OTCQB: PKTX) \n (the \"Company\" or \"ProtoKinetix\") (www.protokinetix.com) \n is pleased to update its stockholders on the progress that it has made \n toward the application to conduct clinical trials in Canada with Health \n Canada.\n \n \n AmbioPharm, \n Inc. of North Augusta, South Carolina, has completed the first run \n of Good Manufacturing Practice (GMP) of AAGP™. AmbioPharm has shipped \n AAGP™ to ITR \n Canada of Montreal, Quebec, to commence toxicology studies under the \n Good Laboratory Practice (GLP).\n \n \n AmbioPharm has also shipped AAGP™ to Nelson \n Laboratories of Salt Lake City, Utah, to commence bio burden and \n development of sterility protocols under GLP.\n \n \n These above tests will provide critical data for the Investigator’s \n Brochure (IB), a component of the clinical trial application to Health \n Canada. The IB is a multidisciplinary document that summarizes the main \n elements of an entire development program to date. Although the IB also \n serves other purposes, it is written to enable investigators conducting \n clinical trial studies to assess the risks and benefits associated with \n an investigational product.\n \n \n To subscribe to our new, automated News Release Email Service, please \n visit our website: www.protokinetix.com\n \n \n About ProtoKinetix\n \n \n ProtoKinetix, Incorporated is a molecular biotechnology company that has \n developed and patented a family of hyper stable, potent glycopeptides \n (AAGP™) that enhance both engraftment and protection of transplanted \n cells used in regenerative medicine. Due to the results achieved over \n the last four years of testing the company is now preparing a submission \n to enter into a Phase 1/2 human clinical trial. Additional studies will \n be expanded to include whole organ transplantation and other cell \n therapies used in regenerative medicine.\n \n \n Cautionary Note Regarding Forward-Looking Statements\n \n \n The information discussed in this press release includes “forward \n looking statements” within the meaning of Section 27A of the Securities \n Act of 1933 (the “Securities Act”) and Section 21E of the Securities \n Exchange Act of 1934 (the “Exchange Act”). All statements, other \n than statements of historical fac...